Russell Investments Group Ltd. Purchases 6,015 Shares of Evolus, Inc. $EOLS

Russell Investments Group Ltd. increased its position in Evolus, Inc. (NASDAQ:EOLS) by 5.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,085 shares of the company’s stock after purchasing an additional 6,015 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.18% of Evolus worth $1,421,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Tang Capital Management LLC grew its stake in Evolus by 3.1% in the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after purchasing an additional 150,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock worth $38,906,000 after purchasing an additional 62,664 shares in the last quarter. Caligan Partners LP grew its stake in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after purchasing an additional 498,900 shares in the last quarter. Millennium Management LLC grew its stake in Evolus by 29.1% in the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock worth $15,107,000 after purchasing an additional 308,753 shares in the last quarter. Finally, Nuveen LLC bought a new position in Evolus in the first quarter worth approximately $12,330,000. Institutional investors own 90.69% of the company’s stock.

Evolus Stock Down 0.9%

Shares of NASDAQ EOLS opened at $7.58 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. The stock has a market capitalization of $490.27 million, a PE ratio of -7.73 and a beta of 1.12. The stock’s fifty day simple moving average is $8.50 and its two-hundred day simple moving average is $10.52. Evolus, Inc. has a 12-month low of $5.71 and a 12-month high of $17.82.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on EOLS shares. HC Wainwright dropped their price objective on Evolus from $27.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. Wall Street Zen cut Evolus from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Needham & Company LLC reaffirmed a “hold” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. Finally, BTIG Research dropped their target price on Evolus from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.25.

Insiders Place Their Bets

In other news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the sale, the chief marketing officer owned 89,949 shares of the company’s stock, valued at $675,516.99. This trade represents a 5.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady Stewart acquired 30,000 shares of the stock in a transaction dated Friday, August 15th. The stock was acquired at an average cost of $6.82 per share, with a total value of $204,600.00. Following the transaction, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 133,627 shares of company stock worth $1,325,764 over the last quarter. Company insiders own 5.90% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.